Across sepsis, CAR-T cytokine release syndrome (CRS), HLH/MAS, and severe viral infections, an overlapping cast of mediators (TNF-α, IL-6, IFN-γ, IL-1β, GM-CSF) drives a feed-forward loop toward vascular leak, organ injury, and death. A neutralizing antibody binds one cytokine (or its receptor) with defined specificity and asks a causal question the profile alone cannot answer. (Schaper & Rose-John, Cytokine Growth Factor Rev 2015).

The Double Blockade fixes anti‑TNF as the upstream arm and pairs it with the IL‑6 axis, since IL‑6 output is only partly TNF‑dependent — neither single cut is complete. The white paper calibrates this honestly: the strongest antibody‑rescued lethal synergy demonstrated to date is TNF‑α + IFN‑γ in HLH/MAS‑like shock (Karki et al., Cell 2021), so the optimal second partner is plausibly etiology‑dependent.

In systemic‑inflammation models the antibody is a first‑class experimental variable: residual endotoxin fires TLR4 and makes the very cytokines under study, while Fc aggregates cross‑link FcγRs and carrier proteins compromise injection. Leinco in vivo grade antibodies are released against an explicit, numeric functional‑grade spec — In Vivo PLATINUM™, pathogen‑free / IMPACT‑tested, carrier‑free and low‑aggregate — so a “neutralizing” reagent cannot quietly become an activator.

Because the inflammatory response is dose‑dependent and timing‑critical — circulating TNF‑α peaks ~90 min after LPS — carrier‑free, high‑concentration material lets you hit a defined kinetic window without reagent endotoxin as a confounder. A single, quality‑controlled panel removes lot‑to‑lot variability as a hidden source of irreproducibility.